Insider Trading February 20, 2026

MACOM CFO Disposes $1.75M in Stock as Company Posts Strong Q1 Results

Senior finance executive sells 7,039 shares under a 10b5-1 plan while the company reports revenue and EPS above expectations and analysts raise targets

By Jordan Park MTSI
MACOM CFO Disposes $1.75M in Stock as Company Posts Strong Q1 Results
MTSI

John Kober, MACOM Technology Solutions' Senior VP and CFO, sold 7,039 shares on February 17, 2026 under a pre-arranged Rule 10b5-1 trading plan, generating roughly $1.75 million. The transaction occurred as the shares traded near a 52-week high, while the company reported first-quarter fiscal 2026 revenue and adjusted EPS that beat guidance and analyst forecasts, prompting price-target increases from Benchmark and Stifel.

Key Points

  • MACOM CFO John Kober sold 7,039 shares on Feb 17, 2026 for about $1.75 million under a Rule 10b5-1 plan - impacts corporate governance and insider liquidity considerations.
  • MACOM reported Q1 fiscal 2026 revenue of $271.6 million and adjusted EPS of $1.02, both exceeding guidance and analyst estimates - signals operational strength across the company's end markets.
  • Benchmark and Stifel raised price targets to $260 and $255 respectively while maintaining Buy ratings, and the company reported a record backlog with a book-to-bill ratio of 1.3 - indicating continued demand and positive analyst sentiment.

MACOM Technology Solutions Holdings, Inc.'s Senior Vice President and Chief Financial Officer, John Kober, executed a sale of company stock on February 17, 2026, according to a recent SEC filing. The filing shows Kober sold 7,039 shares of common stock at prices spanning $236.42 to $247.70, producing an aggregate transaction value of about $1.75 million.

The disclosed trades were made under a pre-established trading plan adopted on August 14, 2025, structured to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. After the reported dispositions, Kober is listed as directly owning 48,508 shares of MACOM.

The sales coincided with MACOM shares trading near their 52-week high of $250, with the stock having returned approximately 96% over the prior 12 months. Separately, analysis available via InvestingPro indicates the stock presently appears overvalued relative to its Fair Value, with more detailed assessment accessible through that platform's Pro Research Report.


Company results and analyst reaction

MACOM released first-quarter fiscal 2026 results that exceeded internal guidance and sell-side estimates. Revenue for the quarter reached $271.6 million, topping both the company guidance midpoint and analyst consensus of $269.0 million. Adjusted earnings per share were reported at $1.02, above the forecasted $0.9973.

The quarterly performance represented a 4.0% sequential increase and a 24.5% year-over-year rise in sales. Management and analysts have pointed to a record backlog and a book-to-bill ratio of 1.3 as supporting evidence of sustained demand across MACOM's end markets.

Following the earnings release, Benchmark raised its price target for MACOM to $260 while maintaining a Buy rating. Stifel also lifted its target to $255 and kept a Buy recommendation. The firms cited the company's strong quarter and guidance as the primary reasons for their continued positive stance.


Context and implications

The insider sale, completed under a Rule 10b5-1 plan established in August 2025, represents a formal mechanism for company insiders to transact in equity while addressing timing and compliance considerations. The company-level results and sell-side responses underscore robust performance during the quarter, balanced by third-party analysis noting potential overvaluation versus Fair Value.

Readers should note that the filing, the company financials, analyst actions, and the InvestingPro assessment are the facts disclosed in public documents and research summaries; additional interpretation or forecasting beyond those items is not provided here.

Risks

  • Insider selling - although executed under an established 10b5-1 plan, the transaction may be viewed by some market participants as reducing insider-held equity - affects investor perception in the equity markets and corporate governance sector.
  • Valuation concerns - InvestingPro analysis indicates MACOM appears overvalued relative to its Fair Value, introducing potential downside risk if market sentiment or fundamentals shift - relevant to equity investors and valuation-sensitive strategies.
  • Reliance on backlog and book-to-bill - while a record backlog and a 1.3 book-to-bill ratio support demand expectations, changes in order flow or end-market conditions could materially affect future revenue - pertinent to the semiconductor and components sectors.

More from Insider Trading

Espey MFG Director Executes Option Exercises, Sells Shares Worth About $130K Feb 20, 2026 Friedman Industries CEO Buys 600 Shares; Company Confirms Dividend and Expands Credit Line Feb 20, 2026 Avidbank Director Rosinus Disposes $126,027 in Stock; Company Posts Mixed Q4 Results Feb 20, 2026 Rogers Corp SVP Michael Reed Webb Sells Shares as Company Posts Strong Q4 Results Feb 20, 2026 Clearfield Director Disposes $115K in Stock as Company Reports Mixed Q1 Results Feb 20, 2026